Trends, Share, Growth, Company Analysis," Diagnostic Imaging Market valued at US$ 35.11 Billion in 2022. Medical imaging uses technology to produce internal body images for clinical analysis or medical intervention in a non-invasive manner. As medical technology advances, the market for Diagnostic Imaging continues to evolve, fuelling the growing demand for patient-centric healthcare. As a result, the industry must focus on critical R&D investments to adapt the constant changes while fulfilling customer needs.
Expert Insights: Ask Analyst or Download Full Report with TOC & Figures: https://www.renub.com/diagnostic-imaging-market-p.php Global Diagnostic Imaging Market is anticipated to with a CAGR of 5.82% from 2022 to 2028With the advent of novel technologies and rapid digitalization, the global medical devices industry is jumping leaps and bounds in growth and development. From new and emerging business models to accelerated innovation in many areas of diagnostics, care delivery, connected health, data security, supply chain, process automation, etc., the healthcare landscape is hovering around the idea of disruptive possibilities owing to several trends. For example, there is a significant shift in R&D spending patterns and talent trends, collaborations with start emphasis on ups, tech giants, service providers, and overall digital and connected health. Medical imaging is one such segment of the MedTech industry that has significantly benefited from the trends mentioned above. X-Ray is primarily used in the Diagnostic Imaging MarketThe primary need for early diagnosis is the cause of the upsurge in X-ray demand. However, along with the need for early diagnosis, factors such as technological advancements in various applications, massive spending in product R&D, growing investments in healthcare infrastructure, and the need for visible improvements in population health technologies are driving the growth in medical imaging. Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=diagnostic-imaging-market-p.php Orthopaedic application segment captured most of the Market ShareThe ever-growing incidence of chronic diseases worldwide, an aging population, rising awareness, and priority for health are increasing the demand for early diagnosis. An additional factor relevant in a scenario is the predominant use of X systems to diagnose COVID ray and CT-19 cases worldwide. As a result, the burden of chronic diseases is rising globally, and medical imaging procedures are crucial in accurately diagnosing chronic diseases. Furthermore, the aging population and socioeconomic changes are leading to a continuous rise in these prevalent and costly long-term health conditions. Cancer, cardiovascular disease, obesity, and diabetes account for the majority of chronic illness mortality. According to GLOBOCAN, around 19.3 million new cancer cases were recorded worldwide in 2020, with this figure anticipated to rise to 30.2 million by 2040. The emerging markets would be the most affected, as population growth is expected to be greatest in developing nations. Hospitals lead the Global Diagnostic Imaging MarketCurrently, hospitals comprise the most significant share; however, the adoption of imaging systems by diagnostic centers is expected to capture the highest CAGR during the upcoming years. The growing number of private imaging centers, fueled by rising demand for diagnostic imaging treatments, is likely to boost hospital segment growth. Companies strive to attain market equilibrium by investing in technology to meet rising demand. From a macroeconomic standpoint, suitable investments bear fruit for all stakeholders in such ecosystems. Furthermore, for instance, in November 2021, Canon Medical Systems USA, Inc., a leading manufacturer of diagnostic devices, announced the launch of Vantage Fortran, an innovative remote tablet and in-room camera solutions for monitoring and positioning patients to enhance workflow. North American region will lead in the Global Diagnostic Imaging MarketNorth America is owing to the higher demand for medical imaging modalities such as Ultrasound, MRI, X-rays, and CT scans in hospital settings for accurate diagnosis during treatment. In addition, the availability of advanced medical imaging devices in hospitals and sound infrastructure leads to the segmental growth of hospitals. Similarly, the presence of skilled healthcare professionals in hospitals to accurately treat and diagnose patients surge the demand for medical imaging in hospitals. Additionally, rising cases of chronic diseases and an increasing number of hospital admissions will further accelerate the medical imaging market progression. Request a free Brochure copy of the report: https://www.renub.com/request-brochure-page.php?gturl=diagnostic-imaging-market-p.php Key Players The worldwide imaging industry is at a crossroads and will profoundly change during the next decade with novel technologies and new players entering and redefining the competitive landscape. The incumbent equipment manufacturers face increasing competition from new entrants such as Samsung Electronics, Neusoft Medical Systems, or Mindray Medical in emerging and developed markets. In addition, the leading contrast media companies will see increasing generic competition as the remaining contrast agent patents expire within the following years. Market Summary:
Browse Related Report: Breast Cancer Screening Market https://bit.ly/40BWxuq Liquid Biopsy Market https://bit.ly/2M3QTiS Autoimmune Disease Diagnostic Market https://bit.ly/2HY25rH About the Company: Renub Research is a Market Research and Information Analysis company with more than 14 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000 syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets. Media Contact: Company Name: Renub Research Contact Person: Rajat Gupta, Marketing Manager Phone No: +1-478-202-3244 | +91-120-421-9822 (IND) Address: 225 Kristie Ln, Roswell, GA 30076 Email: [email protected] LinkedIn: https://in.linkedin.com/company/renub-research
0 Comments
Renub Research has recently published a report named "Germany In-Vitro Diagnostics Market, Size, Forecast 2023-2028, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" providing a detailed industry analysis that consists of market share insights. Furthermore, the report comprises competitor and regional research and contemporary extension in the Germany In-Vitro Diagnostics (IVD) Market. The Germany In-Vitro Diagnostics Market shall expand at a CAGR of 2.44% from 2022 to 2028. In-Vitro Diagnostics (IVD) offers advantages such as early disease detection and diagnosis, personalized medicine through genetic markers, disease monitoring for informed decision-making, improved patient management, preventive care and screening, enhanced treatment selection, increased efficiency, and cost-effectiveness, rapid results, non-invasive testing options, and support for research and development.
Expert Insights: Ask Analyst or Download Full Report with TOC & Figures: https://www.renub.com/germany-in-vitro-diagnostics-market-p.php As per the Federal Statistical Office, Germany will see a significant increase in people at retirement age (67 years or over), reaching at least 20.0 million by the mid-2030s. On the other hand, the population of those aged 80 or over will endure relatively firm during this period, ranging from 5.8 to 6.7 million. The growth of the Germany in-vitro diagnostics (IVD) market is driven by increasing demand for diagnostics testing due to rising chronic diseases and an aging population, advancements in technology enhancing the accuracy and efficiency of in-vitro diagnostics (IVD) tests, a well-established healthcare system with high expenditure supporting accessibility to in-vitro diagnostics (IVD) tests, a growing focus on preventive healthcare and early detection, and favourable government policies promoting innovation and adoption of advanced diagnostic technologies. However, the Germany in-vitro diagnostics (IVD) market faces intense competition, complex regulatory requirements, and reimbursement policies that can impact market dynamics and hinder product innovation. Report Details:Report Features Details Base Year 2022 Historical Period 2018 – 2022 Forecast Period 2023 – 2028 Market US$ Billion Segment Covered Product, Test types, Application, Technology, End-User Companies Covered Roche Diagnostics, Abbott Diagnostics, Siemens Healthineers, Danaher Corporation, Thermo Fisher Scientific, Sysmex Corporation. Customization Scope 20% Free Customization Post-Sale Analyst Support 1 Year (52 Weeks) Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request) Services sector of the Germany in-vitro diagnostics (IVD) market shall witness significant growth. The continuous growth in the services segment of the Germany in-vitro diagnostics (IVD) market can be due to factors such as increasing demand for outsourcing diagnostic services, advancements in technology that require specialized expertise, a focus on cost optimization by healthcare providers, and the need for integrated solutions that streamline laboratory operations and improve patient care. Products–the Germany in-vitro diagnostics (IVD) Market breakup from 3 Viewpoints:
PCR tests have established dominance in the Germany in-vitro diagnostics (IVD) market due to their high accuracy and sensitivity, making them reliable disease detection and diagnosis tools. The versatility of PCR tests allows their application in various areas, including infectious disease testing, genetic testing, and oncology. Furthermore, the rapid turnaround time of PCR tests enables prompt decision-making and treatment planning. Again, continuous advancements in PCR technology have improved test performance, automation, and cost-effectiveness, making them accessible to healthcare providers. In addition, the COVID-19 pandemic has increased the demand for PCR tests, solidifying their position as the gold standard for SARS-CoV-2 detection. Overall, the dominance of PCR tests in the Germany in-vitro (IVD) market arises from their accuracy, broad applications, quick results, technological progress, and the influence of the pandemic. Test types - Germany in-vitro diagnostics (IVD) Market breakup from 11 Viewpoints:
Cardiology sector exhibits the highest growth rate in the Germany in-vitro diagnostics market. The prevalence of cardiovascular diseases fuels the demand for advanced cardiology diagnostics in Germany. In-vitro diagnostics play a vital role in the early detection and management of these conditions. Technological advancements improve cardiac diagnostics' accuracy, efficiency, and risk assessment. Additionally, the aging population contributes to the increased demand for these diagnostic tests. In-vitro tests provide valuable information on biomarkers and genetic markers related to cardiovascular health. Preventive healthcare strategies prioritize early detection and intervention, with non-invasive diagnostics being pivotal in preventing cardiac diseases. Point-of-care testing expands access to rapid diagnostics, enhancing patient care. Furthermore, favourable reimbursement policies drive the adoption of cardiology diagnostics, contributing to the growth of the Germany in-vitro diagnostics (IVD) market. Application - the Germany in-vitro diagnostics (IVD) Market breakup from 8 Viewpoints:
Molecular diagnostics/genetics has grown substantially in the Germany in-vitro diagnostics (IVD) market. The growth of molecular diagnostics/genetics in the Germany in-vitro diagnostics (IVD) market can be due to advancements in technology, improved accuracy and efficiency of tests, the genetic understanding of diseases, rising prevalence of genetic disorders and cancer, valuable insights into disease risk and treatment response, availability of comprehensive genetic testing panels and next-generation sequencing technologies, favorable regulatory policies and reimbursement schemes, and collaborative efforts between research institutions, diagnostic companies, and healthcare providers. Technology - the Germany in-vitro diagnostics (IVD) Market breakup from 7 Viewpoints:
Laboratories shall gain popularity in the Germany in-vitro diagnostics (IVD) market. The growth of laboratories in the Germany in-vitro diagnostics market is because of the increasing demand for diagnostic services, driven by the rising prevalence of diseases and the need for accurate diagnoses. Technological advancements have enhanced laboratory testing efficiency, with automation and sophisticated techniques improving accuracy and speed. The complexity of diagnostic testing, particularly in molecular diagnostics and genetics, necessitates specialized expertise and advanced equipment. Accreditation ensures quality and instills confidence in test results. Specialized laboratories cater to the trend toward personalized medicine and precision diagnostics. Integration of information systems streamlines operations and improves communication. End-User - the Germany in-vitro diagnostics (IVD) Market breakup from 4 Viewpoints:
Competitive Landscape Prominent companies in the Germany in-vitro diagnostics (IVD) market include Roche Diagnostics, Abbott Diagnostics, Siemens Healthineers, Danaher Corporation, Thermo Fisher Scientific, and Sysmex Corporation. Company have been covered from 3 Viewpoints: 1. Overview 2. Recent Development 3. Revenue Company Analysis:
Related ReportsJapan In-Vitro Diagnostics (IVD) Market Italy In-Vitro Diagnostics Market Europe In-Vitro Diagnostics Market About the Company: Renub Research is a Market Research and Information Analysis company with more than 14 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000 syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets. Media Contact: Company Name: Renub Research Contact Person: Rajat Gupta, Marketing Manager Phone No: +1-478-202-3244 | +91-120-421-9822 (IND) Address: 225 Kristie Ln, Roswell, GA 30076 Email: [email protected] LinkedIn: https://linkedin.com/company/renub-research Web: www.renub.com Renub Research has recently released a report titled " Multiple Myeloma Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" providing a detailed industry analysis that includes market share insights. In addition, the report covers research on competitors and regions and current advancements in the multiple myeloma market. The Multiple Myeloma Industry shall experience a CAGR of nearly 6.04% from 2023 to 2028. The increasing prevalence of multiple myeloma is aiding the rise of the multiple myeloma market. Expert Insights: Ask Analyst or Download Full Report with TOC & Figures: https://www.renub.com/multiple-myeloma-market-p.php American Society of Clinical Oncology (ASCO) projects that approximately 35,730 adults in the United States, comprising 19,860 men and 15,870 women, will receive a multiple myeloma diagnosis in 2023, with an estimated 12,590 deaths, including 7,000 men and 5,590 women, resulting from the disease in the same year. The aging population worldwide has also contributed to the development of this market. The United Nations Population Division's new world population report estimates that the number of people aged 80 or over is projected to triple, from 157 million in 2022 to 459 million in 2050. Moreover, the availability of advanced diagnostics tools and the development of novel therapies have improved the survival rate of multiple myeloma patients, leading to increased demand for these treatments. For instance, Takeda carried out Phase I/Phase II multicenter trials in December 2022 to examine the safety, efficacy, tolerability, and immunogenicity of Modakafusp Alfa in patients with relapsed or refractory multiple myeloma. Additionally, the increasing adoption of targeted therapies and the use of combination therapies have also contributed to the growth of the multiple myeloma market. Furthermore, the rising investments in research and development activities by pharmaceutical companies and academic institutions have resulted in the development of more effective and efficient treatments for multiple myeloma. For example, in March 2022, Sanofi entered into a strategic collaboration with Blackstone on a risk-sharing basis. As per the collaboration, Blackstone Life Sciences would invest up to EUR 300 million (USD 320.51 million) to expedite the pivotal global studies and clinical development program for Sarclisa, an anti-CD38 antibody, for treating multiple myeloma patients via subcutaneous formulation and delivery. Lastly, the increasing awareness about multiple myeloma and the availability of treatment options among patients and healthcare professionals have also contributed to the growth of the multiple myeloma market. Targeted Therapy dominance in the multiple myeloma market due to Selective Cancer Cell Targeting and Personalized Treatment Plans with practical outcomes The reason for the dominance of targeted therapy in the multiple myeloma market is its ability to selectively target cancer cells while sparing healthy cells, resulting in fewer side effects and better outcomes for patients. Additionally, targeted therapies can be customized to a patient's specific cancer type and genetic profile, allowing personalized treatment plans. Another factor contributing to the dominance of targeted therapy in the multiple myeloma market is its effectiveness in treating multiple myeloma, with many targeted therapies showing high response rates and improved survival rates in clinical trials. Finally, the approval of several new targeted therapies for multiple myeloma in recent years has expanded treatment options for patients, further contributing to the growth and dominance of this market segment. Aging Population of Females is increasing the prevalence of Multiple Myeloma in Women, benefiting the multiple myeloma market The growth of female patients in the multiple myeloma market can be due to increased awareness and early disease diagnosis among women, leading to better detection and treatment. Moreover, as the population ages, more women are developing multiple myeloma, and the risk of the disease increases with age. Furthermore, an increasing number of clinical trials are focusing on the study of multiple myeloma in female patients, which is helping to improve our knowledge of the disease and provide more efficient treatment alternatives for women. 𝑭𝒐𝒓 𝑴𝒐𝒓𝒆 𝑫𝒆𝒕𝒂𝒊𝒍𝒔, 𝑮𝒓𝒂𝒃 𝒕𝒉𝒆 Free Sample Report: https://www.renub.com/request-sample-page.php?gturl=multiple-myeloma-market-p.php France robust Healthcare System and Favorable Regulatory Environment contributed to its growing Epidemiology Share in the Multiple Myeloma Market France robust healthcare system strongly emphasizes cancer screening and early detection, resulting in the identification and reporting of more multiple myeloma cases, which played a significant role in the growth of France's epidemiology share in the multiple myeloma market. The country also has an intense research and development infrastructure for cancer treatments, which can lead to better treatment outcomes and longer survival rates for multiple myeloma patients attracting more patients to seek treatment in France, contributing to the country's epidemiology share. In addition, France has a favorable regulatory environment for clinical trials, which can attract pharmaceutical companies to conduct tests in the country leading to more innovative treatments becoming available in France, further contributing to the country's epidemiology share. United States (U.S.) has the Lion's Share in the Multiple Myeloma MarketThe U.S. has a large patient population with multiple myeloma, which makes it an attractive market for pharmaceutical companies to invest in and develop new treatments. According to the American Cancer Society, approximately 35,730 individuals shall receive a new diagnosis of multiple myeloma in the United States in 2023, with an estimated 12,590 deaths to occur as a result of the disease. Therefore, conducting clinical trials and studies on a larger patient population provides an opportunity for more comprehensive data and evidence on treatment effectiveness. The U.S. has a favorable regulatory environment for clinical trials and drug approvals, encouraging pharmaceutical companies to conduct studies and bring products to market quickly. In addition, a stable economy provides a conducive environment for investments in research and development, making the U.S. an attractive market for stakeholders in the multiple myeloma market. Market Summary:
About the Company: Renub Research is a Market Research and Information Analysis company with more than 14 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000 syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets. Contact Us:Renub Research Phone No: +1-478-202-3244 | +91-120-421-9822 (IND) Email: [email protected] LinkedIn: https://in.linkedin.com/company/renub-research Web: www.renub.com Renub Research has recently released a report titled "Medical Robotics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2030," providing a detailed industry analysis that includes market share insights. The report also includes competitor and regional research and contemporary advancements in the market. According to this research report Medical Robotics Market shall be US$ 72.22 Billion in 2030. Medical robots are specialized in hospitals, clinics, and research facilities to perform specific medical tasks like surgery, diagnosis, and rehabilitation. These robots have advanced sensors, cameras, and other tools, allowing them to perform precise and complex procedures with minimal human intervention. Examples of medical robots include surgical, rehabilitation, and diagnostic robots.
Expert Insights: Ask Analyst or Download Full Report with TOC & Figures: https://www.renub.com/medical-robotics-market-p.php Technological advancements in medical robotics market have expanded their capabilities, leading to better patient outcomes and increased efficiency in medical procedures. Improved precision and accuracy are achieved through advanced sensors and cameras, reducing human error and minimizing complications. High-resolution cameras provide detailed views, enhancing visualization and improving accuracy. Increased automation reduces the need for human intervention, resulting in faster procedures and improved patient safety. In addition, healthcare professionals can integrate medical robots with other technologies, such as 3D printing and virtual reality, and enable minimally invasive procedures, reducing recovery time and improving patient comfort. Medical robots market have transformed healthcare, resulting in better patient outcomes, reduced costs, and increased efficiency. Medical robots industry has some drawbacks, including high acquisition and maintenance costs, which can limit access to medical procedures for some patients. Medical robots also require specialized training and expertise, which can be time-consuming and costly. Moreover, medical robots depend on complex technology, making them vulnerable to technical issues that can cause the postponement or cancellation of medical procedures, affecting patient outcomes. Pharmacy application Improves Medication Management which adds to its Growth Pharmacy applications can improve medication management by reducing errors and providing real-time tracking, especially in surgical settings with multiple medications. They increase efficiency by automating tasks and improving patient outcomes with accurate medication information. Pharmacy applications can also lower costs by reducing manual management and improving inventory. As the medical robotics industry grows, the use of pharmacy applications shall become more prevalent. The orthopedic medical robot market pertains to the utilization of robotic technology across a range of orthopedic procedures. With the capacity to elevate the precision and accuracy of surgical interventions, medical robots are progressively gaining acceptance in the orthopedic market, leading to better patient outcomes and quicker recovery periods. Additionally, these robots enable surgeons to achieve better visualization and control during surgery, diminishing the likelihood of complications and boosting patient safety. Given the increasing demand for orthopedic procedures, it is anticipated that the medical robots market in orthopedics will continue expanding in the foreseeable future. Hospitals remain the dominant user Preference in Medical Robotics Market Hospitals have more significant financial and technological resources than other healthcare providers, making investing in expensive medical robotics systems easier. In addition, the frequent use of medical robotics systems for complex surgical procedures every day in hospitals. Finally, hospitals often have dedicated research and development departments, keeping them up-to-date with the latest advancements in medical robotics technology and allowing them to adopt new systems as they become available. Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=medical-robotics-market-p.php Specialized medical facilities, such as cancer centers, cardiac centers, and neurology centers, have started utilizing robotics technology in the medical robot industry. This increasing adoption is because medical robots enhance the precision and accuracy of medical procedures, resulting in better patient outcomes and faster recovery times. As the demand for specialized medical treatments continues to grow, the medical robot industry in specialty centers is predicted to continue expanding in the upcoming years. North America has hegemony in the Global Medical Robotics Market North America dominates the medical robotics market as it has a developed healthcare infrastructure, technologically advanced hospitals, and high healthcare expenditure, facilitating investment in medical robotics. As a result, many major medical robotics companies are based in the region, driving innovation and development. Additionally, the area has a favorable regulatory environment, a large patient population with high disposable income and insurance coverage, and a strong focus on research and development, leading to the development of advanced medical robotics technology. In the Asia Pacific region, the medical robotics market is expected to witness significant growth during the forecast period. This growth can be attributed to various factors, such as the governments' efforts to promote technological advancements in the pharmaceutical sector, which is leading to greater accessibility and investment in medical robotics. The demand for medical robots in China is primarily driven by the adoption of instrument-based services, as well as a shortage of skilled physiotherapists and caretakers. In addition, the Australian medical robotics sector is highly advanced, as evidenced by the recent introduction of Versius, a surgical robot designed to reduce the physical demands on surgeons. This development highlights Australia's position in the medical robotics market. Competitive Landscape Analysis The medical robotics Market is multiplying, offering new entrants and established companies’ opportunities to expand their product offerings. Healthcare providers demand medical robotics systems to improve patient outcomes, increase efficiency, and reduce costs. The industry's wide range of applications creates diverse opportunities for specialization. Technological advancements and innovations drive competition, and the global market with companies from different regions vying for market share further fuels it. Some major companies operating in the market are IRobot, Intuitive Surgical, Stryker, Accuray, Medtronic, Smith & Nephew, McKesson, and Ekso Bionics Holdings. Market Summary:
Key Players - All the major players in the report Medical Robotics Market have been covered from 3 Viewpoints (Overview, Recent Developments, and Revenue) IRobot, Intuitive Surgical, Stryker, Accuray, Medtronic, Smith & Nephew, McKesson, and Ekso Bionics Holdings. Browse Related Report: Ophthalmic Device Market https://www.renub.com/ophthalmic-devices-market-p.php Trauma Fixation Device Market https://www.renub.com/worldwide-trauma-fixation-device-market-and-forecast-519-p.php Cardiac Bio Implant Devices Market https://www.renub.com/cardiac-bio-implant-devices-market-p.php Respiratory Care Devices Market https://www.renub.com/respiratory-care-devices-market-p.php About the Company: Renub Research is a Market Research and Information Analysis company with more than 14 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000 syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets. Media Contact: Company Name: Renub Research Contact Person: Rajat Gupta, Marketing Manager Phone No: +1-478-202-3244 | +91-120-421-9822 (IND) Address: 225 Kristie Ln, Roswell, GA 30076 Email: [email protected] LinkedIn: https://in.linkedin.com/company/renub-research Web: www.renub.com Global Radiology Information System Market is expected to reach US$ 1,388.5 Million by 20271/13/2023 According to Renub Research latest report by titled "Radiology Information System Market, Size, Global Forecast 2022-2027, Industry Trends, Share, Growth, Insight, Impact of COVID-19, Company Analysis," Radiology Information System Market will reach US$ 1,388.5 Million in 2027. According to Globocan, 19,292,789 new cancer cases and 9,958,133 deaths from cancer were reported in 2020. An upsurge in cancer cases will focus on radiology services for a proper diagnosis to derive the market demand for radiology information systems. Furthermore, the RIS is a computer system that delivers business analysis and an effective strategy in the radiology department. The system supports dealing with all the department's business functions, from patient management and accounting to inventory control. These systems are easy to utilize and are simply accessible. In addition, they offer benefits like reliability, high security, and privacy, and only authorized users can access them.
Radiology Information System Market was US$ 843.9 Million in 2021: The drivers for the growth of the RIS market include: • Improved access to healthcare information technology systems. • The increasing incidence rate of chronic diseases. • The rise in government funding for cancer-related research. Moreover, the burden of chronic diseases is increasing across the globe, along with the growing aging population, and lifestyle-related disorders, such as arthritis, cancer, cardiovascular, and diabetes, are some of the primary issues responsible for the growth of this market. The Integrated Radiology Information System is Expected to Witness High Growth over the Forecast Period: The radiology information system market is segmented by type. It includes Integrated Radiology Information System and Standalone Radiology Information System. The Integrated Radiology Information System segment is expected to grow at the highest CAGR during the forecast period. By deployment mode, it is segmented into web-based, on-premises, and cloud-based. The web-based segment accounts for siginificant segmental revenue in the Radiology Information Systems market in 2021. Web-based RIS is developed to help link patient information to any desired destination to grow clinical and business needs around the continuum of care. Radiology Information System Market Size is likely to expand at a CAGR of 8.65% during 2021 – 2027: Depending on geographic regions, the demand for radiology information systems is segmented into North America, Europe, Asia Pacific, and Middle East & Africa. North America has the greatest market for the sales of radiology information systems and is providing the most compared to other regions. This is owing to the enhanced demand of the diagnostic industry to get faster, better, and more effective results. COVID-19 Impact: COVID-19 had a significant impact on the radiology information system industry. In April 2020, as per the article "Impact of COVID-19 on Radiology Practices," published in the Radiological Society of North America, the policy measures approved to slow the transmission of COVID-19 reduced the need for imaging services. In addition, the guidelines from the CDC (Centres for Disease Control and Prevention) to postpone emergency outpatient visits during the pandemic significantly impacted screening services like lung cancer screening and mammography, and the effect has been observed across the radiology sector. This will likely impact the demand for RIS as they are used to analyse data from radiology units. Competitive Landscape: The key market players in the radiology information system market are Cerner Corporation, Mckesson Corporation, Varian Medical Systems Inc., Fujifilm Holdings Corporation, Hologic, Inc, General Electric, and Koninklijke Philips N.V. Contact Us: Renub Research Phone No: +1 678-302-0700 (USA) | +91–120–421–9822 (IND) Email: [email protected] Web: https://www.renub.com Follow on Linkedin: https://www.linkedin.com/company/renub-research Follow on Twitter: @renubresearch According to Renub Research report titled, “Adult Vaccine Market, Size, Global Forecast 2022-2027, Industry Trends, Growth, Impact of COVID-19, Opportunity Company Analysis” the Global Adult Vaccine Market is estimated to reach USD 18.8 Billion by 2021. Over the years, vaccine-preventable diseases have been killing thousands of adults each year worldwide. Vaccines, surprisingly, are used to prevent infections and boost the body's immunity. Hence, adult vaccination has become one of the most cost-effective public health interventions accessible today. Moreover, it is also a biological preparation that comprises an agent that looks like a disease-causing germ created from weakened and destroyed microorganisms.
Global Adult Vaccine Industry Is Projected to Grow with A CAGR of 6% From 2021-2027: Some of the major drivers for the global adult vaccines market are increased illness prevalence and novel vaccination technologies. Furthermore, increased research in the field of vaccine technology and increasing government backing are all contributing to the global adult vaccines market's growth. Several government agencies are funding and granting research on customized vaccinations to improve their efficacy and disease-prevention potential. In addition, some government organizations are putting in place particular requirements for their safe practices. Increased R&D investment by pharmaceutical and biopharmaceutical companies and widespread R&D pipelines are expected to help move the worldwide adult vaccines market forward. Request a Free Sample Copy of the Report: https://www.renub.com/request-sample-page.php?gturl=adult-vaccines-market-company-adult-vaccines-sales-country-adult-vaccines-worldwide-analysis-19-p.php Disease wise – Adult Vaccines Market & Numbers of Adults Vaccinated: In our report, Coronavirus (COVID-19), Influenza, Cervical Cancer (HPV), Zoster (Shingles), MMR (Measles, Mumps, and Rubella Vaccine), Pneumococcal, Meningococcal, Hepatitis, TdaP, and Varicella are the diseases included. Furthermore, due to the growing negative worries about prevalent infectious diseases, which are the leading causes of mortality and morbidity worldwide, the number of immunizations for various diseases is at an all-time high. Further, the worldwide number of adult vaccines vertical has seen significant expansion due to the continual increase in demand for immunization against severe diseases such as cholera, typhoid, hepatitis, measles, chickenpox, and many others. On the other hand, several molecular entities are through substantial research and development stages and are aimed at immunizing against deadly diseases. Key Players in the Global Adult Vaccine Industry: The significant companies studied in the global adult vaccine market include GlaxoSmithKline, plc, Merck & Co.'s, Sanofi Pasteur's, Pfizer, Inc.'s, and Thoracic Aortic Aneurysm (TAA) CSL Limited's. As per our analysis, the key players are focusing on business expansion to increase their revenue share by implementing mergers and acquisitions and new product development strategies. For instance, GlaxoSmithKline plc announced in 2021 that they had submitted a (BLA) Biologics License Application to the US Food and Drug Administration for their investigational vaccine PRIORIX, requesting authorization to use it against measles, mumps, and rubella (MMR) in the United States. The vaccine was first registered in Germany and is now approved in more than 100 countries worldwide. COVID-19's Impact on the Global Adult Vaccine Market: The COVID-19 pandemic had a diverse impact on the global adult vaccine industry. Vaccination rates for some vaccines have decreased. On the other hand, vaccination rates for a few vaccines, such as flu vaccines, have increased. The introduction of COVID-19 vaccines has significantly impacted the vaccine industry's overall growth. Furthermore, we aim to see the global adult vaccines market to quantify the health, economic, and social benefits of vaccines and immunization programs to individuals and society. Follow the link for the full report with detailed TOC and list of figures and tables: https://www.renub.com/adult-vaccines-market-company-adult-vaccines-sales-country-adult-vaccines-worldwide-analysis-19-p.php Market Summary:
About the Company: Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food & Beverages, Power & Energy, Information Technology, Telecom & Internet, Chemical, Logistics & Automotive, Consumer Goods & Retail, Building, and Construction, & Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more. Our research helps to make business decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We support many blue chip companies by providing them with findings and perspectives across a wide range of markets. Our research reports offer a blend of information insight, analysis, and forecasting that is essential in today's ultra-competitive markets. Contact Us: Renub Research Phone No: +1 678-302-0700 (USA) | +91–120–421–9822 (IND) Email: [email protected] Web: https://www.renub.com Follow on Linkedin: https://www.linkedin.com/company/renub-research Follow on Twitter: @renubresearch As per the latest report by Renub Research titled "United States Anesthesia Drugs Market, Size, Forecast 2022-2027, Share, Growth, Industry Trends, Impact of COVID-19, Opportunity Company Analysis" United States Anesthesia Drugs Market Size was US$ 4.9 Billion by 2027. In the United States, anesthesia drug is one of the milestones in the pharmaceutical industry, which benefits patients with painless treatment and impossible to perform surgery. The US is home to bigwigs in the pharmaceutical sector to increase their stakes in the United States market. Anesthesia meant the condition of holding sensation blocked or temporarily taken away. This authorizes the patient to undergo surgery and other procedures without distress and pain they would otherwise experience. Anesthesia drugs are used while performing surgical procedures to control pain, heart rate, blood pressure, breathing, rhythm, and blood flow.
Top Impacting Factors: Notwithstanding, the United States anesthesia drug market is driven by the rising number of surgeries, the growing aging population with increasing chronic conditions, and advancements in anesthesia technologies. As per the statistics provided by the (ASPS) American Society of Plastic Surgeons, in 2019, nearly 16.3 Million cosmetic minimally-invasive procedures and 1.8 Million cosmetic surgical were performed in the United States. Request a Free Sample Copy of the Report: https://www.renub.com/request-sample-page.php?gturl=united-states-anesthesia-drugs-market-and-forecast-31-p.php Furthermore, the demand for various anesthetics goes hand-in-hand with the performed surgical procedures. The application of anesthetics in general surgeries is anticipated to contribute significantly to the market's growth in the United States. Further, new anesthesia drugs are being developed, which is predicted to propel market growth. For instance, in 2020, Medova and the New York School of Regional Anesthesia (NYSORA) entered a partnership to introduce SAFIRA (SAFer Injection for Regional Anesthesia) in the United States. COVID-19 Impact on Anesthesia Drugs Industry: In the United States, the demand for anesthesia drugs seen a slight drop in 2020 due to the emergence of the pandemic situation, cancelled surgeries or leading to delayed. With the emergence of COVID-19, the United States faced extreme shortages of vital anesthesia drugs, mainly canceled surgeries, dexmedetomidine, midazolam, Propofol, and neuromuscular blocking agents. Most of the surgeries were delayed, and only acute surgical emergencies were managed. Thus, the COVID-19 has an unfavorable impact on the United States anesthesia drugs industry. As a result, numerous players are ramping up their production of anesthesia drugs. For instance, in 2020, Hikma Pharmaceutical introduced a new product, "Propofol Injectable Emulsion," in the United States. General Inhalation Anesthesia is the Leading Segments in the United States Anesthesia Market Based on type, the United States anesthesia drugs market includes the General Inhalation Anesthesia Drugs market, General Intravenous Anesthesia Drugs Market, and Local Anesthesia Drugs Market. General Inhalation Anesthesia Drugs Market holds a considerable market share; the inhaled anesthetics include desflurane, isoflurane, sevoflurane, and others that enhance inhibit excitatory synaptic activity and inhibitory postsynaptic channel activity. General intravenous anesthesia drugs are less costly and do not need expensive machines for administration. Moreover, intravenous anesthesia drugs result in undersized cardiovascular depression and better postoperative analgesia. Besides, general intravenous anesthesia is the leading segment in the United States Anesthesia Market. Fospropofol Disodium, Propofol, Benzodiazepines Class, Ketamine, Methohexital Sodium, Pentobarbital, Etomidate, and Fentanyl are generally utilized general intravenous anesthesia in the United States. Propofol drug is one of the most frequently used general anesthetics in surgeries among these anesthesia drugs. It is utilized as a sedative for critical care (including COVID-19) in the ICU. It is used to maintain procedural sedation, initiate general anesthesia, etc. In 2020, the United States (FDA) Food & Drug Administration approved the usage of Fresenius Propoven 2% emulsion to maintain sedation in COVID-19 patients (16 years and above) requiring mechanical ventilation. Competitive Landascape The United States anesthesia drugs market is highly competitive and consists of several major players. Most of the anesthesia drugs trade is generic and are available at a low cost. The key players include Draegerwerk AG, Abbvie, Baxter International Inc., Endo International plc, and Koninklijke Philips NV. Follow the link for the full report with detailed TOC and list of figures and tables: https://www.renub.com/united-states-anesthesia-drugs-market-and-forecast-31-p.php Market Summary:
About the Company: Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food & Beverages, Power & Energy, Information Technology, Telecom & Internet, Chemical, Logistics & Automotive, Consumer Goods & Retail, Building, and Construction, & Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more. Our research helps to make business decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We support many blue chip companies by providing them with findings and perspectives across a wide range of markets. Our research reports offer a blend of information insight, analysis, and forecasting that is essential in today's ultra-competitive markets. Contact Us: Renub Research Phone No: +1 678-302-0700 (USA) | +91–120–421–9822 (IND) Email: [email protected] Web: https://www.renub.com Follow on Linkedin: https://www.linkedin.com/company/renub-research Follow on Twitter: @renubresearch As per the latest report by Renub Research titled "Oncology Precision Medicine Market, Size, Global Forecast 2022-2027, Share, Growth, Industry Trends, Impact of COVID-19, Opportunity Company Analysis" the Global Oncology Precision Market Size will reach USD 64.66 Billion by 2027. Oncology precision medicine is an emerging trend in the healthcare industry that has been growing quickly in recent years. It makes the diagnosis of cancer and other diseases more accurate and evaluates the specific genetic makeup of their tumors to select the safest and most effective treatments for them. In cancer, precision medicine involves sampling DNA from patients' tumors to determine the mutations or other genetic changes that drive their cancer. Physicians then may select a treatment for a particular patient's cancer that best matches, or targets, the culprit mutations in the tumor DNA.
Likewise, some of the more common cancers where precision medicine is being used to help with treatment decisions include Lung Cancer, Stomach Cancer, Prostate Cancer, Liver Cancer, Oesophagus Cancer, Colorectal Cancer, Breast Cancer, r, cervical cancer, Kidney Cancer, and Bladder Cancer. Notwithstanding, the existing oncology precision medicine market is preferred by multiple factors, including several government initiatives, rising cancer incidences, and death rates, coupled with the general population's growing awareness about molecular-level diagnosis and treatment. Besides, the increasing number of advancements in molecular diagnostics, increasing FDA approvals for such precision medicine-based oncology drugs, enhancing focus on research and development activities by crucial healthcare companies also led to market expansion. Furthermore, the development of newer therapeutic approaches, including gene therapy for cancer treatment and a rising number of patients undergoing predictive diagnosis, will propel the market growth. Request a Free Sample Copy of the Report: https://www.renub.com/request-sample-page.php?gturl=oncology-precision-medicine-market-p.php COVID-19 Impact on Oncology Precision Market COVID-19 has impacted the oncology precision medicine market. This impact was mainly due to disturbance of the supply chain and lockdowns imposed in many countries. Nevertheless, as the lockdowns were raised and supply was restored, the market has recovered quickly. As precision medicine deals majorly with fatal disorders like cancer involving life-saving drugs, the COVID-19 pandemic is poised to impact the market during the assessment period. Majorly for individuals living with cancer, the pandemic posed a unique set of challenges. The pandemic has certainly hindered surgeries and testing on biopsy tissue and has also impacted cancer patients' ability to receive provider-administered drugs. Thus, the volume of oncology precision drugs and services declined notably in 2020. Hospital end-users accounted for the largest share of the global oncology precision medicine market On the basis of end-user, the global oncology precision medicine market is categorized into Hospitals, Diagnostic Centers, Research & Academic Institutes, and Others. The hospital's segment accounted for the most significant market. The large share of this segment is primarily attributed to the rising number of tertiary/specialty care hospitals, rising incidence of cancer diseases, growing healthcare infrastructure, increasing demand for quality healthcare, and shift towards personalized/precision medicine. As per our research findings, Worldwide oncology precision medicine market was USD 33.40 Billion in 2021 North Americans raise oncology precision medicine production: Geographically, North America is leading the oncology precision medicine market. The number of cancer patients in North America is growing notably. According to the (ACS) American Cancer Society, cancer is the leading reason of death in Canada and the second leading cause of death in the U.S. In U.S, about 1.8 million new cancer cases were diagnosed in 2020. High awareness in the region regarding precision medicine and increasing demand for personalized cancer treatment will drive the industry revenue in the region. The level of medical procedures, such as radiation, chemotherapy, and immunotherapy required, will depend upon the stage and type of cancer. Precision medicines play an essential role in helping physicians determine a suitable treatment plan based on the current genetic mutations of the patient. Similarly, oncology precision medicine treatments have gained momentum among clients in the Asia-Pacific region in the past few years. They utilize advanced technologies and innovative methods to create personalized medicines that cater to patients' medical needs. The global precision medicine market players are Eli Lily and Co., F. Hoffmann – La Roche Ltd, Novartis AG, Bristol–Myers Squibb and AstraZeneca. Follow the link for the full report with detailed TOC and list of figures and tables: https://www.renub.com/oncology-precision-medicine-market-p.php Market Summary:
About the Company: Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food & Beverages, Power & Energy, Information Technology, Telecom & Internet, Chemical, Logistics & Automotive, Consumer Goods & Retail, Building, and Construction, & Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more. Our research helps to make business decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We support many blue chip companies by providing them with findings and perspectives across a wide range of markets. Our research reports offer a blend of information insight, analysis, and forecasting that is essential in today's ultra-competitive markets. Contact Us: Renub Research Phone No: +1 678-302-0700 (USA) | +91–120–421–9822 (IND) Email: [email protected] Web: https://www.renub.com Follow on Linkedin: https://www.linkedin.com/company/renub-research Follow on Twitter: @renubresearch As per the latest report by Renub Research titled “Pediatric Vaccines Market, Size, Forecast 2022-2027, Share, Growth, Industry Trends, Impact of COVID-19, Opportunity Company Analysis" Pediatric Vaccines Market Size was US$ 47.8 Billion by 2021. The vaccines administered to stop children from contracting several infectious diseases and non-infectious are pediatric vaccines. These vaccines are heat-killed or inactivated viruses that lose their pathogenicity, i.e., the ability to cause disease. Additionally, these inactivated antigens can stimulate the immune system to produce antibodies against the infected virus.
Besides, pediatric vaccines are distributed to a child in its pediatric age, from 0 –18 years. Vaccines are commonly given to prevent children from diseases transferred through seasonal variations, infections, and even though unhygienic areas. Depending upon the disorder, the vaccines are administered at regular intervals. World Health Organization (WHO) has designed a standard immunization program to have desired time interval between vaccines doses. Pediatric Vaccine Growth Factors Globally, the growing prevalence of chronic disorders such as diphtheria, tuberculosis, and pneumonia in the age of 15 years and downward will contribute to the development of the pediatric vaccines industry. According to WHO, globally around 5 billion severe illnesses and 0.5 billion deaths yearly. As immunization plays a vital role in modern medicine, several international programs for children may vary based on the disease. Nevertheless, these programs are primarily driving the demand in the pediatric vaccines market. Further, the global pediatric vaccines market is driven by factors such as the global initiative undertaken by key players to develop innovative vaccines and increase government support. Request a Free Sample Copy of the Report: https://www.renub.com/request-sample-page.php?gturl=pediatric-vaccines-market-p.php The Combos Vaccine Segment is to Grow at a Significant Rate: Based on Vaccine Types, the Pediatric Vaccine industry includes Influenza, MMR (Measles, Mumps, and Rubella Vaccine), Pneumococcal, Meningococcal, Hepatitis, DTaP, mophilus Influenzae Type B (HIB), Combos (Combination), Polio, Rotavirus, Varicella and Coronavirus (COVID-19). Infections are always a leading cause of mortality and morbidity in children under 5 years of age, most of which can be stopped by vaccination. However, too many vaccines are to be administered, increasing the cost of immunization and visits to the pediatrician. Combination vaccines can answer these problems until developing a single vaccine containing all the possible antigens. Additionally, combination vaccines such as the 5-in-1 and the MMR have been developed to help reduce the number of injections needed. Even so, children and babies often receive several vaccines at once. For example, a 2-month-old baby will simultaneously obtain the 5-in-1, PCV, Rotavirus, and MenB vaccines. Moreover, as per our Report statistics, the number of infants vaccinated from Combination Vaccines across the world was 163.52 Million in 2021, and it increased appreciably to 339.04 Million by 2027. COVID-19 Impact on Global Pediatric Vaccines Market: The COVID-19 has upended the lives of children and their families. Therefore, amidst the pandemic, the global market for Pediatric vaccines dropped in 2020 as most healthcare personnel were busy in COVID-19 management. The pandemic naturally affected the routine immunization programs and campaigns conducted globally in developing and developed countries. The UNICEF and World Health Organization (WHO) warned of an alarming drop in the number of children receiving life-saving vaccines worldwide. This is due to troubles in the delivery and uptake of immunization services caused by the COVID-19 pandemic. Regardless, Influenza vaccination rates have gone up considerably during the pandemic due to push from health experts/health departments and the extension of different government programs that provide free vaccination against the flu. Also, growing awareness among the public about the higher risk of getting infected with COVID-19 if the flu weakens the immune system is another factor contributing to the uptake of flu vaccines. Key Players: The pediatric vaccines industry consists of several major players, including GlaxoSmithKline, Plc, Merck & Co., Sanofi Pasteur’s, Pfizer, Inc.’s, CSL Limited. The companies enforce specific strategic initiatives like new product launches, mergers, acquisitions, and partnerships, which help them strengthen their market position. Follow the link for the full report with detailed TOC and list of figures and tables: https://www.renub.com/pediatric-vaccines-market-p.php Market Summary:
About the Company: Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food & Beverages, Power & Energy, Information Technology, Telecom & Internet, Chemical, Logistics & Automotive, Consumer Goods & Retail, Building, and Construction, & Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more. Our research helps to make business decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We support many blue chip companies by providing them with findings and perspectives across a wide range of markets. Our research reports offer a blend of information insight, analysis, and forecasting that is essential in today's ultra-competitive markets. Contact Us: Renub Research Phone No: +1 678-302-0700 (USA) | +91–120–421–9822 (IND) Email: [email protected] Web: https://www.renub.com Follow on Linkedin: https://www.linkedin.com/company/renub-research Follow on Twitter: @renubresearch As per the latest report by Renub Research titled “Global Dialysis Market, Size, Forecast 2022-2027, Share, Growth, Industry Trends, Impact of COVID-19, Opportunity Company Analysis" Global Dialysis Market Size was USD 92.5 Billion in 2021. Worldwide, dialysis is an essential and life-saving treatment for chronic renal failure (CRF), kidney diseases, end-stage renal disease (ESRD). Dialysis is a treatment that purifies blood using a machine. It utilizes special equipment to remove excess water and waste products from the blood. In this procedure, the blood is filtered, excess toxins and fluid are removed, and electrolyte balance is restored. Dialysis is carried out in two ways: peritoneal and hemodialysis dialysis. Both perform the usual filtering of waste kidney functions and excess fluid from the blood.
Key Factors Driving the Growth of the Dialysis Industry: Dialysis market growth is driven by the increasing diabetic population, higher prevalence among ageing population, and rising cases of ESRD are anticipated to drive the market. Further, an increase in the advancement of home-based services and the number of treatment centers are the aspects attributing toward the dominance of the services segment. Moreover, improved reimbursement policies for renal treatment by private and public institutions are encouraging the expansion of the market at a remarkable rate. For instance, in 2020, according to the End-Stage Renal Disease (ESRD) PPS final rule, the Centers for Medicare & Medicaid Services (CMS) to pay around US$ 10.3 billion in Medicare reimbursements to about 7,000 ESRD providers for the costs of delivering renal hemodialysis services. Request a Free Sample Copy of the Report: https://www.renub.com/request-sample-page.php?gturl=global-dialysis-market-p.php How Coronavirus Affected the Dialysis Industry Besides, the COVID-19 pandemic had a moderate impact on the market. COVID-19 is majorly a respiratory disease, but it has also been shown to impact kidneys, damaging the organ to cause acute renal infection (AKI). The pandemic also disrupted the supply chain operations and affected the availability of hemodialysis, consumables for peritoneal dialysis, and essential medicines, leading to a drop in dialysis procedures performed in several dialysis centers. Due to such adverse scenarios, the overall impact of the COVID-19 pandemic on the market is to be substantial. Hemodialysis to Account for Maximum Share Based on type, the dialysis market is bifurcated into hemodialysis and peritoneal dialysis. The hemodialysis segment is a significant contributor to the dialysis market growth. Hemodialysis helps balance minerals such as sodium, calcium, and potassium that aids in decreasing blood pressure. Routine hemodialysis is conducted in a hospital, dialysis outpatient facility, or a dedicated stand-alone clinic that surges the market demand. Also, the growing prevalence of chronic kidney diseases across the globe will boost the acceptance rate of hemodialysis among the patient population base. Hemodialysis is classified into short daily, conventional hemodialysis, hemodialysis, and nocturnal hemodialysis. In terms of end-users, the dialysis market is segmented into in-center and home dialysis. Dialysis treatments centers accounted for the significant market, attributable to the favorable reimbursement provided by renal facilities. Most patients prefer to obtain dialysis treatments through services delivered by dialysis centers making them the most significant contributor to the global dialysis market. Regardless, a rise in awareness and surge in demand for home healthcare among dialysis patients is predicted to make home dialysis the fastest-growing segment during the forecast period. Home dialysis offers several benefits, including reducing travel expenses, improved quality of life, flexibility, and accessible patient mobility. Rising Dialysis Cases in the North American Region will Fuel the Industry's Progression: Amongst regions worldwide, North America is projected to lead the dialysis market owing to the higher usage of dialysis therapy to treat several end-stage renal diseases and chronic kidney diseases. The high prevalence of CKD and ESRD in the U.S. and Canada, coupled with higher treatment rates in these countries, are the pivotal factors estimated to boost the expansion of the market during the forecast period. Further, the North American region is projected to see growth attributable to the growing incidence of coronavirus infections and succeeding renal failures. Likewise, the Asia-Pacific region is anticipated to witness the growth in dialysis market during the coming year, which is attributed to a low rate of organ transplantation, surge in the incidence rate of kidney failure, and advancement in healthcare expenditure. Follow the link for the full report with detailed TOC and list of figures and tables: https://www.renub.com/global-dialysis-market-p.php Competitive Landscape The prominent players operating in the dialysis market include Baxter International Inc, Fresenius Medical Care, DaVita Inc, Asahi Kasei Corporation, and Medtronic Plc. These variant market participants are undertaking various progressive strategies to capture a higher revenue share in this dialysis market. Several development strategies enforced by foremost market players have helped them maintain a strong position in the industry. Market Summary:
About the Company: Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food & Beverages, Power & Energy, Information Technology, Telecom & Internet, Chemical, Logistics & Automotive, Consumer Goods & Retail, Building, and Construction, & Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more. Our research helps to make business decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We support many blue chip companies by providing them with findings and perspectives across a wide range of markets. Our research reports offer a blend of information insight, analysis, and forecasting that is essential in today's ultra-competitive markets. Contact Us: Renub Research Phone No: +1 678-302-0700 (USA) | +91–120–421–9822 (IND) Email: [email protected] Web: https://www.renub.com Follow on Linkedin: https://www.linkedin.com/company/renub-research Follow on Twitter: @renubresearch |
Archives
November 2021
Categories
All
|